Clinical trial
Gamma-Amino Butyric Acid (GABA) Deficits and Vulnerability to Cannabinoid-Induced Psychosis
NCT00982982 is registered in ClinicalTrials.gov with Yale University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Gamma-Amino Butyric Acid (GABA) Deficits and Vulnerability to Cannabinoid-Induced Psychosis
- Lead sponsor
- Yale University
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 11, 2009
- Completion date
- February 22, 2013
- Enrollment
- 17 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.